Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

https://ift.tt/7IHisUh

 

from Sanofi - Aventis Groupe https://ift.tt/z2ouJMf
via IFTTT